search
Back to results

Real-Time Antiretroviral Therapy Adherence Intervention in Uganda

Primary Purpose

HIV/AIDS, Adherence

Status
Completed
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
Fixed SMS, real-time monitoring
Triggered SMS, real-time monitoring
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV/AIDS focused on measuring HIV/AIDS, adherence, real time monitoring, SMS, mHealth, social support

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Wisepill Participants:

Inclusion Criteria:

  • HIV-infected
  • Initiating ART within the next two weeks
  • Age 18 years and older
  • Owns a cell phone for personal use and has reliable cellular phone reception at home on a network supported by the technology used in this study
  • Lives in the Mbarara District (i.e, within 20 km of the ISS Clinic)
  • Has at least one person who could be named as a social supporter(see criteria below).

Exclusion Criteria:

  • Unable to use SMS
  • Unwilling to receive SMS reminders
  • Severe mental condition limiting the ability to provide consent
  • Cellular phone reception is not reliable

Social supporters (i.e., recipients of the SMS notifications for Wisepill participants in the intervention arms):

Inclusion criteria:

  • Knows Wisepill participant has HIV
  • Age 18 years or older
  • Reports having provided social support to the intervention participant at least once
  • Own a cell phone for personal use and have reliable cellular phone reception at home on a network supported by the technology used in this study
  • Lives in the Mbarara District

Exclusion criteria:

  • Unable to use SMS
  • Unwilling to receive SMS notifications regarding interruptions in the intervention participant's adherence
  • Severe mental condition limiting the ability to provide consent

Sites / Locations

  • Mbarara Immune Suppression Syndrome(ISS) Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

Fixed SMS, real-time monitoring

Triggered SMS, real-time monitoring

control

Arm Description

SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.

Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.

Real-time adherence monitoring only (no SMS)

Outcomes

Primary Outcome Measures

Antiretroviral Therapy (ART) Adherence Levels
ART adherence in each study arms. Adherence is measured by the Wisepill real-time adherence monitor and calculated as the number of monitor opening signals received divided by the number of monitor opening signals expected, capped at 100%.

Secondary Outcome Measures

HIV RNA Suppression
HIV RNA suppression (<100 copies/ml) in each study arm

Full Information

First Posted
September 25, 2013
Last Updated
March 23, 2017
Sponsor
Massachusetts General Hospital
Collaborators
Mbarara University of Science and Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT01957865
Brief Title
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
Official Title
Development of a Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Mbarara University of Science and Technology

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Development of Real-Time Antiretroviral Therapy Adherence Intervention in Uganda (The Wisepill Study).
Detailed Description
In this study, the investigators propose to develop a real-time adherence intervention based on SMS (i.e., text messages), wireless adherence monitoring (with the Wisepill device), and engagement of social support that is tailored to rural sub-Saharan Africa. The investigators will build on research by others who have shown SMS reminders improve adherence and viral suppression in Kenya, albeit with relatively small effect sizes and suboptimal virologic failure rates even in the intervention arm. Moreover, little is known about which patients benefit from SMS, why they benefit, and what can be done to further improve adherence and treatment success rates. Understanding the mechanisms of effect will make it possible to design and test evidence-based interventions with the highest likelihood for efficacy. In a cohort of HIV-infected individuals starting ART and being monitored with Wisepill, the investigators will test 1) daily SMS reminders, 2) weekly SMS reminders, 3) SMS reminders linked to real-time detection of missed doses, and 4) SMS reminders plus SMS notifications of 48+hour gaps in adherence to members of social support networks. The investigators will conduct qualitative interviews to learn the experiences of participants and members of their social support networks with the different types of SMS. This staged approach will allow us to fully understand and compare the additive effects and acceptability of SMS-based interventions. The investigators will also determine behavioral effect mechanisms, as well as compare the impact of each type of SMS with a control population receiving only Wisepill monitoring on adherence and HIV RNA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS, Adherence
Keywords
HIV/AIDS, adherence, real time monitoring, SMS, mHealth, social support

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
63 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fixed SMS, real-time monitoring
Arm Type
Experimental
Arm Description
SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
Arm Title
Triggered SMS, real-time monitoring
Arm Type
Experimental
Arm Description
Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
Arm Title
control
Arm Type
No Intervention
Arm Description
Real-time adherence monitoring only (no SMS)
Intervention Type
Device
Intervention Name(s)
Fixed SMS, real-time monitoring
Other Intervention Name(s)
Wisepill
Intervention Description
SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
Intervention Type
Device
Intervention Name(s)
Triggered SMS, real-time monitoring
Other Intervention Name(s)
Wisepill
Intervention Description
SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
Primary Outcome Measure Information:
Title
Antiretroviral Therapy (ART) Adherence Levels
Description
ART adherence in each study arms. Adherence is measured by the Wisepill real-time adherence monitor and calculated as the number of monitor opening signals received divided by the number of monitor opening signals expected, capped at 100%.
Time Frame
real time (for 9 months)
Secondary Outcome Measure Information:
Title
HIV RNA Suppression
Description
HIV RNA suppression (<100 copies/ml) in each study arm
Time Frame
After month 9

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Wisepill Participants: Inclusion Criteria: HIV-infected Initiating ART within the next two weeks Age 18 years and older Owns a cell phone for personal use and has reliable cellular phone reception at home on a network supported by the technology used in this study Lives in the Mbarara District (i.e, within 20 km of the ISS Clinic) Has at least one person who could be named as a social supporter(see criteria below). Exclusion Criteria: Unable to use SMS Unwilling to receive SMS reminders Severe mental condition limiting the ability to provide consent Cellular phone reception is not reliable Social supporters (i.e., recipients of the SMS notifications for Wisepill participants in the intervention arms): Inclusion criteria: Knows Wisepill participant has HIV Age 18 years or older Reports having provided social support to the intervention participant at least once Own a cell phone for personal use and have reliable cellular phone reception at home on a network supported by the technology used in this study Lives in the Mbarara District Exclusion criteria: Unable to use SMS Unwilling to receive SMS notifications regarding interruptions in the intervention participant's adherence Severe mental condition limiting the ability to provide consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jessica Haberer, MD, MS
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Angella Musiimenta, PhD
Organizational Affiliation
Mbarara University of Science and Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mbarara Immune Suppression Syndrome(ISS) Clinic
City
Mbarara
State/Province
Mbarara District
Country
Uganda

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data will be available at the end of the study upon request.
Citations:
PubMed Identifier
30626191
Citation
Musiimenta A, Atukunda EC, Tumuhimbise W, Haberer JE. Resilience after withdrawing a technology-based medication adherence support intervention from people living with HIV in rural Uganda. AIDS Care. 2018 Aug;30(sup5):S89-S96. doi: 10.1080/09540121.2018.1510107. Epub 2019 Jan 9.
Results Reference
derived
PubMed Identifier
29773527
Citation
Musiimenta A, Atukunda EC, Tumuhimbise W, Pisarski EE, Tam M, Wyatt MA, Ware NC, Haberer JE. Acceptability and Feasibility of Real-Time Antiretroviral Therapy Adherence Interventions in Rural Uganda: Mixed-Method Pilot Randomized Controlled Trial. JMIR Mhealth Uhealth. 2018 May 17;6(5):e122. doi: 10.2196/mhealth.9031.
Results Reference
derived
PubMed Identifier
26760452
Citation
Haberer JE, Musiimenta A, Atukunda EC, Musinguzi N, Wyatt MA, Ware NC, Bangsberg DR. Short message service (SMS) reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda. AIDS. 2016 May 15;30(8):1295-300. doi: 10.1097/QAD.0000000000001021.
Results Reference
derived

Learn more about this trial

Real-Time Antiretroviral Therapy Adherence Intervention in Uganda

We'll reach out to this number within 24 hrs